Carboxy Therapy Market Size to Hit $228.7 million by 2031: Coherent Market Insights
June 13, 2024 10:45 ET
|
CMI
Burlingame, June 13, 2024 (GLOBE NEWSWIRE) -- The global carboxy therapy market size was estimated at USD 107.7 million in 2024 and is expected to reach around USD 228.7 million by 2031, registering...
Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland
June 12, 2024 08:00 ET
|
Quoin Pharmaceuticals, Inc.
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles...
Aesthetic Loop Launches A New Platform for Medical Aesthetics Professionals
June 07, 2024 17:16 ET
|
Aesthetic Loop
Irvine, CA, June 07, 2024 (GLOBE NEWSWIRE) -- Healthcare professionals in the Medical Aesthetics industry often face the challenge of finding secure and private spaces for candid discussions and...
$6.97 Billion Photodynamic Therapy Market Outlook, 2024-2032, Featuring Detailed Analysis of Gladerma, Sun Pharmaceutical Industries, Biofrontera, Lumibird, Bausch Health Companies, and More
June 06, 2024 04:22 ET
|
Research and Markets
Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Photodynamic Therapy Market Report by Product Types, Application, End-user, Countries and Company Analysis 2024-2032" report has been added to ...
Online Dermatology Consultation Analysis 2024: Global Market to Surpass $7.5 Billion by 2029, Driven by Demand for Accessibility in Remote Areas and Prompt Patient Referrals
June 04, 2024 11:47 ET
|
Research and Markets
Dublin, June 04, 2024 (GLOBE NEWSWIRE) -- The "Online Dermatology Consultation Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering. The online...
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis
May 28, 2024 07:35 ET
|
Numab Therapeutics AG
Numab Therapeutics Announces J&J to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for AD
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 20, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
May 16, 2024 06:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel and Beimei Pharma annouce an Asset Purcase Agreement to commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
May 15, 2024 16:01 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 13, 2024 16:01 ET
|
Journey Medical Corporation
New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7%...